Castellum (CTM) director receives 100,000 stock options at $1.19
Castellum, Inc. (CTM) disclosed an insider equity award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Castellum, Inc. (CTM) disclosed an insider equity award. Director Bernard S. Champoux was granted 100,000 stock options on 11/11/2025 with an exercise price of $1.19 per share under the Second Amended 2021 Stock Incentive Plan. The options vest ratably over twenty months starting December 1, 2025 and expire on 11/10/2032. The filing lists ownership as Direct (D). This is a routine compensation grant to a board member, not an open‑market purchase or sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 100,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. As compensation for his service as an independent member of the Board of Directors, Mr. Champoux received 100,000 stock options granted pursuant to the terms of the Castellum, Inc. Second Amended 2021 Stock Incentive Plan to purchase 100,000 shares of common stock which vest ratably over a period of twenty months commencing December 1, 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Castellum (CTM) disclose in this Form 4?
What are the vesting terms of the CTM director’s options?
When do the granted CTM options expire?
What is the ownership form reported for the options?
Under which plan were the CTM options granted?
Is this a market transaction or compensation grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.